ViferaXS raises up to €12 million to advance CLLTAXS01 into a randomized Phase II trial in chronic lymphocytic leukemia and support Phase I programs.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
German clinical-stage biotechnology company ViferaXS has secured up to €12 million in Series A financing, including grant funding, led by the German Federal Agency for Breakthrough Innovation (SPRIND) and Huma, with participation from private investors.
The financing will primarily support the company’s lead program, CLLTAXS01, as it advances into a randomized Phase II study in CLL. The funds will also support ongoing Phase I development in AML and FLC, along with additional preclinical work and team expansion.
The company has not disclosed the detailed financing structure or the individual contributions from participating investors.
Peptide-Based T-Cell Activation Approach
ViferaXS is developing cancer immunotherapies based on its proprietary T Cell Activator technology, which activates cytotoxic T cells against naturally presented tumor antigens.
The approach is being evaluated across both hematologic malignancies and solid tumors. Its clinical pipeline currently includes AML, CLL, and FLC, providing an opportunity to assess the platform across diseases with different tumor biology and treatment requirements.
For CLL, the move into Phase II follows early clinical findings with CLLTAXS01. However, the company has not disclosed detailed efficacy, safety, or patient-level clinical data in the financing announcement.
CLL Program Moves Toward Randomized Phase II
CLLTAXS01 will now enter a randomized Phase II study in patients with CLL. The financing announcement did not provide the planned enrollment, comparator arm, dosing regimen, primary endpoint, or statistical analysis plan.
These details will be important for assessing whether the early clinical signal can translate into clinically meaningful activity in a controlled study.
CLL remains a major hematologic malignancy in adults, with treatment strategies increasingly shaped by targeted therapies and molecular disease characteristics. Demonstrating clinically relevant activity in this setting will therefore require evaluation against established treatment outcomes and a well-defined safety profile.
Phase I Read-outs Expected in AML and FLC
Alongside the CLL program, ViferaXS expects to report Phase I data from its AML and FLC programs.
The upcoming read-outs could provide the first broader clinical assessment of the company’s T Cell Activator platform across hematologic and solid tumor settings. The company has not yet disclosed specific timing or topline efficacy and safety measures for these datasets.
CEO Sezai Taskin said the financing will allow the company to take the early CLLTAXS01 findings into randomized Phase II development while advancing the AML and FLC programs.
SPRIND Innovation Manager Patrick Rose, PhD, said the agency’s investment reflects its focus on supporting high-ambition technologies with potential for significant societal and economic impact.
Huma Founder and CEO Dan Vahdat said the company will support ViferaXS through both investment and its clinical-trial technology platform.
Next Development Milestones
The immediate clinical milestone is initiation and execution of the Phase II CLLTAXS01 program. ViferaXS will also generate Phase I data from its AML and FLC programs and continue preclinical development in additional indications.
The company is a spin-out of the University of Tübingen and is headquartered in Tübingen, Germany. The new financing provides funding to advance its lead program while establishing clinical data across multiple cancer indications, with the forthcoming Phase II and Phase I read-outs expected to provide the next substantive evidence for its peptide-based immunotherapy platform.
Reference
ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline, ViferaXS GmbH, 23 September 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.